# Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer

> **NCT00209651** · PHASE2 · UNKNOWN · sponsor: **Hokkaido Gastrointestinal Cancer Study Group** · enrollment: 40 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Campto, Topotesin
- **DRUG:** TS-1

## Key facts

- **NCT ID:** NCT00209651
- **Lead sponsor:** Hokkaido Gastrointestinal Cancer Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2007-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2007-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00209651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00209651, "Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00209651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*